CA3033633A1 - Compositions for treating ischemia/reperfusion injury - Google Patents

Compositions for treating ischemia/reperfusion injury Download PDF

Info

Publication number
CA3033633A1
CA3033633A1 CA3033633A CA3033633A CA3033633A1 CA 3033633 A1 CA3033633 A1 CA 3033633A1 CA 3033633 A CA3033633 A CA 3033633A CA 3033633 A CA3033633 A CA 3033633A CA 3033633 A1 CA3033633 A1 CA 3033633A1
Authority
CA
Canada
Prior art keywords
bag3
ischemia
reperfusion injury
reperfusion
levels
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3033633A
Other languages
English (en)
French (fr)
Inventor
Arthur M. Feldman
Joseph Y. CHEUNG
Kamel Khalili
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Temple Univ School of Medicine
Original Assignee
Temple Univ School of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Temple Univ School of Medicine filed Critical Temple Univ School of Medicine
Publication of CA3033633A1 publication Critical patent/CA3033633A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA3033633A 2016-08-11 2017-08-10 Compositions for treating ischemia/reperfusion injury Pending CA3033633A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662373410P 2016-08-11 2016-08-11
US62/373,410 2016-08-11
PCT/US2017/046237 WO2018031738A2 (en) 2016-08-11 2017-08-10 Ischemia/reperfusion injury

Publications (1)

Publication Number Publication Date
CA3033633A1 true CA3033633A1 (en) 2018-02-15

Family

ID=61162527

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3033633A Pending CA3033633A1 (en) 2016-08-11 2017-08-10 Compositions for treating ischemia/reperfusion injury

Country Status (10)

Country Link
US (2) US20190183971A1 (https=)
EP (1) EP3496726A4 (https=)
JP (1) JP7164885B2 (https=)
KR (2) KR20240130829A (https=)
CN (1) CN109937045A (https=)
AU (2) AU2017311405B2 (https=)
CA (1) CA3033633A1 (https=)
IL (2) IL264760B2 (https=)
MX (1) MX2019001729A (https=)
WO (1) WO2018031738A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110438159B (zh) * 2019-07-03 2023-02-28 广州中医药大学(广州中医药研究院) 一种引发肌原纤维肌病的基因突变小鼠模型的构建方法
CN113082048B (zh) * 2021-05-08 2022-06-10 中国人民解放军陆军军医大学第二附属医院 一种Se@BSA纳米药物的制备方法及其在急性肾损伤中的应用
CN113502260A (zh) * 2021-07-16 2021-10-15 新疆医科大学第一附属医院 一种小鼠乳鼠原代心肌细胞分离与培养方法及其应用
JP2025514489A (ja) * 2022-05-03 2025-05-02 テンプル ユニバーシティー オブ ザ コモンウェルス システム オブ ハイアー エデュケーション 脳におけるｂａｇ３およびタンパク質品質管理

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834248A (en) * 1995-02-10 1998-11-10 Millennium Pharmaceuticals Inc. Compositions and methods using rchd534, a gene uregulated by shear stress
US20030175958A1 (en) * 2002-03-15 2003-09-18 Reed John C. Methods for using bag expression as a cell differentiation agent and marker
CN102170911B (zh) 2008-08-01 2014-07-02 克里夫兰生物实验室公司 用于治疗再灌注损伤的方法
KR101436684B1 (ko) * 2012-03-09 2014-09-01 가톨릭대학교 산학협력단 저산소성 허혈 예방 또는 치료용 조성물
WO2015117010A2 (en) * 2014-01-31 2015-08-06 Temple University Of The Commonwealth System Of Higher Education Bag3 as a target for therapy of heart failure

Also Published As

Publication number Publication date
JP2019527736A (ja) 2019-10-03
IL264760B1 (en) 2023-03-01
AU2023237152B2 (en) 2026-01-22
EP3496726A4 (en) 2020-05-06
KR20240130829A (ko) 2024-08-29
KR20190042609A (ko) 2019-04-24
US20190183971A1 (en) 2019-06-20
CN109937045A (zh) 2019-06-25
IL300767A (en) 2023-04-01
MX2019001729A (es) 2019-11-12
US20230390357A1 (en) 2023-12-07
AU2023237152A1 (en) 2023-10-19
JP7164885B2 (ja) 2022-11-02
IL264760B2 (en) 2023-07-01
IL264760A (https=) 2019-03-31
WO2018031738A2 (en) 2018-02-15
EP3496726A2 (en) 2019-06-19
IL300767B1 (en) 2026-03-01
AU2017311405B2 (en) 2023-07-13
AU2017311405A1 (en) 2019-02-28

Similar Documents

Publication Publication Date Title
AU2023237152B2 (en) Ischemia/Reperfusion injury
US8513007B2 (en) SDF-1 delivery for treating ischemic tissue
US20250001014A1 (en) Bag3 compositions and methods
CA2996975C (en) Methods for treatment of diseases
JP2022547111A (ja) 治療用融合タンパク質
JP2019527736A5 (https=)
US11560412B2 (en) Compositions comprising GRIM-19 therapeutics and methods of use
US12577292B2 (en) Ferritin nanocage for multi-displaying trail trimer and cancer-targeting peptide and use thereof as anticancer agent
US11944671B2 (en) Hippo pathway deficiency reverses systolic heart failure post-infarction
US12605398B2 (en) CRISPR-based compositions for treating vascular disorders
US20090181911A1 (en) Role of gax in alzheimer neurovascular dysfunction
KR102267495B1 (ko) 미토콘드리아 타겟팅용 폴리펩타이드 및 그 용도
HK40056903B (zh) 用於疾病治疗的方法
CN115957301A (zh) 一种促进心梗心肌修复的细胞分泌因子及应用
HK1258994B (zh) 用於疾病治疗的方法
HK1129392A (en) Phosphatase inhibitor protein-1 as a regulator of cardiac function

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220714

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20240730

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250103

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED

Effective date: 20250218

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT

Effective date: 20250221

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250221

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250221

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250221

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250221

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250617

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250617

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250920

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250922

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D164 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: RESPONSE TO NOTICE OF ALLOWANCE

Effective date: 20251201

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT

Effective date: 20260309

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260309